154 related articles for article (PubMed ID: 24242862)
1. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
Jeong W; Rapisarda A; Park SR; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Cancer Chemother Pharmacol; 2014 Feb; 73(2):343-8. PubMed ID: 24292632
[TBL] [Abstract][Full Text] [Related]
3. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
[TBL] [Abstract][Full Text] [Related]
4. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Garrett CR; Bekaii-Saab TS; Ryan T; Fisher GA; Clive S; Kavan P; Shacham-Shmueli E; Buchbinder A; Goldberg RM
Cancer; 2013 Dec; 119(24):4223-30. PubMed ID: 24105075
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
[TBL] [Abstract][Full Text] [Related]
9. [Combination with SN-38 on human colon cancer LoVo cells].
Wang Y; Xu JM; Xu QZ; Zhou PK; Song ST
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):746-851. PubMed ID: 20021826
[TBL] [Abstract][Full Text] [Related]
10. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
11. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
Greenberger LM; Horak ID; Filpula D; Sapra P; Westergaard M; Frydenlund HF; Albaek C; Schrøder H; Ørum H
Mol Cancer Ther; 2008 Nov; 7(11):3598-608. PubMed ID: 18974394
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
[TBL] [Abstract][Full Text] [Related]
14. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
Kummar S; Raffeld M; Juwara L; Horneffer Y; Strassberger A; Allen D; Steinberg SM; Rapisarda A; Spencer SD; Figg WD; Chen X; Turkbey IB; Choyke P; Murgo AJ; Doroshow JH; Melillo G
Clin Cancer Res; 2011 Aug; 17(15):5123-31. PubMed ID: 21673063
[TBL] [Abstract][Full Text] [Related]
15. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.
Uronis HE; Jia J; Bendell JC; Howard L; Ready NA; Lee PH; Starr MD; Dellinger A; Pang H; Nixon AB; Hurwitz HI
Cancer Chemother Pharmacol; 2015 Feb; 75(2):343-52. PubMed ID: 25527204
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
Uronis HE; Cushman SM; Bendell JC; Blobe GC; Morse MA; Nixon AB; Dellinger A; Starr MD; Li H; Meadows K; Gockerman J; Pang H; Hurwitz HI
Cancer Med; 2013 Jun; 2(3):316-24. PubMed ID: 23930208
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Guion-Dusserre JF; Lorgis V; Vincent J; Bengrine L; Ghiringhelli F
World J Gastroenterol; 2015 Feb; 21(7):2096-101. PubMed ID: 25717243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
